# NCT06614192 (NCT06614192)

> A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06614192
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Metastatic Colorectal Cancer
- Interventions: Telisotuzumab Adizutecan
- Enrollment: 74
- Primary outcome: Percentage of Participants with Adverse Events (AE)s
- Primary outcome: Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator
- Primary outcome: Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as Assessed by the Investigator
- Primary outcome: Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Coagulation, and Urinalysis) as Assessed by the Investigator
- Primary outcome: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## HCP commentary on NCT06614192 so far

What clinicians have said in podcasts, YouTube videos and X posts we have indexed. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06614192